RCAT is trading 5.1% down at $9.59 as investors digest a lingering dilution overhang from a recent public offering and broader market weakness.

  • The stock is facing pressure from the recent offering alongside profit-taking following a significant prior run-up in share price.
  • Broader market sentiment is soft, with the Nasdaq down 1.04%, which often adds pressure to high-momentum names.
  • Shares are trading lower than the July 6 close of $10.11, with no new company-specific catalysts reported for July 7.